Provides cleaning chemistries and sterility assurance products for healthcare facilities. Offers automated endoscope reprocessing systems and tracking products. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
The market pays 26.2× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 64% of them.
Analysts' average target sits 29% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 9% a year on average.
It pays out $2.58 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, STE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: STE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.